TiumBio begins patient dosing in phase 2 trial of oral immuno-oncology drug TU2218: Republic of Korea Monday, October 7, 2024, 12:00 Hrs [IST] TiumBio Co., Ltd., a clinical-stage ...
Some results have been hidden because they may be inaccessible to you